Results of cardiovascular outcome trials (CVOT) have shown that treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) is associated with cardiovascular protection in diabetic patients with established atherosclerotic cardiovascular disease (ASCVD) and in those with higher ASCVD risk with benefits observed also in patients older than 65 years of age [21–30]. The gene discussed is GLP1R; the disease is atherosclerosis.